BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 16943266)

  • 1. Diabetes risk associated with use of olanzapine, quetiapine, and risperidone in veterans health administration patients with schizophrenia.
    Lambert BL; Cunningham FE; Miller DR; Dalack GW; Hur K
    Am J Epidemiol; 2006 Oct; 164(7):672-81. PubMed ID: 16943266
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antipsychotic exposure and type 2 diabetes among patients with schizophrenia: a matched case-control study of California Medicaid claims.
    Lambert BL; Chou CH; Chang KY; Tafesse E; Carson W
    Pharmacoepidemiol Drug Saf; 2005 Jun; 14(6):417-25. PubMed ID: 15786516
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term antipsychotic monotherapy for schizophrenia: disease burden and comparative outcomes for patients treated with olanzapine, quetiapine, risperidone, or haloperidol monotherapy in a pan-continental observational study.
    Dossenbach M; Pecenak J; Szulc A; Irimia V; Anders M; Logozar-Perkovic D; Peciukaitiene D; Kotler M; Smulevich AB; West TM; Lowry AJ; Treuer T
    J Clin Psychiatry; 2008 Dec; 69(12):1901-15. PubMed ID: 19012820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia.
    Sernyak MJ; Leslie DL; Alarcon RD; Losonczy MF; Rosenheck R
    Am J Psychiatry; 2002 Apr; 159(4):561-6. PubMed ID: 11925293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence of newly diagnosed diabetes attributable to atypical antipsychotic medications.
    Leslie DL; Rosenheck RA
    Am J Psychiatry; 2004 Sep; 161(9):1709-11. PubMed ID: 15337666
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol.
    Dossenbach M; Erol A; el Mahfoud Kessaci M; Shaheen MO; Sunbol MM; Boland J; Hodge A; O'Halloran RA; Bitter I;
    J Clin Psychiatry; 2004 Mar; 65(3):312-21. PubMed ID: 15096069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of falls and fractures in older adults using atypical antipsychotic agents: a propensity score-adjusted, retrospective cohort study.
    Chatterjee S; Chen H; Johnson ML; Aparasu RR
    Am J Geriatr Pharmacother; 2012 Apr; 10(2):83-94. PubMed ID: 22306198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rate of new-onset diabetes among patients treated with atypical or conventional antipsychotic medications for schizophrenia.
    Ollendorf DA; Joyce AT; Rucker M
    MedGenMed; 2004 Jan; 6(1):5. PubMed ID: 15208518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of discontinuation of atypical antipsychotic agents in the treatment of schizophrenia.
    Mullins CD; Obeidat NA; Cuffel BJ; Naradzay J; Loebel AD
    Schizophr Res; 2008 Jan; 98(1-3):8-15. PubMed ID: 17596914
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Are all commonly prescribed antipsychotics associated with greater mortality in elderly male veterans with dementia?
    Rossom RC; Rector TS; Lederle FA; Dysken MW
    J Am Geriatr Soc; 2010 Jun; 58(6):1027-34. PubMed ID: 20487081
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study.
    Stroup TS; Lieberman JA; McEvoy JP; Swartz MS; Davis SM; Capuano GA; Rosenheck RA; Keefe RS; Miller AL; Belz I; Hsiao JK;
    Am J Psychiatry; 2007 Mar; 164(3):415-27. PubMed ID: 17329466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retrospective cohort study of diabetes mellitus and antipsychotic treatment in a geriatric population in the United States.
    Feldman PD; Hay LK; Deberdt W; Kennedy JS; Hutchins DS; Hay DP; Hardy TA; Hoffmann VP; Hornbuckle K; Breier A
    J Am Med Dir Assoc; 2004; 5(1):38-46. PubMed ID: 14706127
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect on lipid profiles of switching from olanzapine to another second-generation antipsychotic agent in veterans with schizophrenia.
    Garman PM; Ried LD; Bengtson MA; Hsu C; McConkey JR
    J Am Pharm Assoc (2003); 2007; 47(3):373-8. PubMed ID: 17510032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antipsychotics, other psychotropics, and the risk of death in patients with dementia: number needed to harm.
    Maust DT; Kim HM; Seyfried LS; Chiang C; Kavanagh J; Schneider LS; Kales HC
    JAMA Psychiatry; 2015 May; 72(5):438-45. PubMed ID: 25786075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frequency of sexual dysfunction and other reproductive side-effects in patients with schizophrenia treated with risperidone, olanzapine, quetiapine, or haloperidol: the results of the EIRE study.
    Bobes J; Garc A-Portilla MP; Rejas J; Hern Ndez G; Garcia-Garcia M; Rico-Villademoros F; Porras A
    J Sex Marital Ther; 2003; 29(2):125-47. PubMed ID: 12623765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How effective is it to sequentially switch among Olanzapine, Quetiapine and Risperidone?--A randomized, open-label study of algorithm-based antipsychotic treatment to patients with symptomatic schizophrenia in the real-world clinical setting.
    Suzuki T; Uchida H; Watanabe K; Nomura K; Takeuchi H; Tomita M; Tsunoda K; Nio S; Den R; Manki H; Tanabe A; Yagi G; Kashima H
    Psychopharmacology (Berl); 2007 Dec; 195(2):285-95. PubMed ID: 17701027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized, flexible-dose, quasi-naturalistic comparison of quetiapine, risperidone, and olanzapine in the short-term treatment of schizophrenia: the QUERISOLA trial.
    Sacchetti E; Valsecchi P; Parrinello G;
    Schizophr Res; 2008 Jan; 98(1-3):55-65. PubMed ID: 17933497
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Weight gain in patients with schizophrenia treated with risperidone, olanzapine, quetiapine or haloperidol: results of the EIRE study.
    Bobes J; Rejas J; Garcia-Garcia M; Rico-Villademoros F; García-Portilla MP; Fernández I; Hernández G;
    Schizophr Res; 2003 Jul; 62(1-2):77-88. PubMed ID: 12765747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A 24-week, multicenter, open-label, randomized study to compare changes in glucose metabolism in patients with schizophrenia receiving treatment with olanzapine, quetiapine, or risperidone.
    Newcomer JW; Ratner RE; Eriksson JW; Emsley R; Meulien D; Miller F; Leonova-Edlund J; Leong RW; Brecher M
    J Clin Psychiatry; 2009 Apr; 70(4):487-99. PubMed ID: 19358783
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
    Lieberman JA; Stroup TS; McEvoy JP; Swartz MS; Rosenheck RA; Perkins DO; Keefe RS; Davis SM; Davis CE; Lebowitz BD; Severe J; Hsiao JK;
    N Engl J Med; 2005 Sep; 353(12):1209-23. PubMed ID: 16172203
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.